Clorox Co
Change company Symbol lookup
Select an option...
CLX Clorox Co
SNCY Sun Country Airlines Holdings Inc
NCZ Virtus Convertible & Income Fund II
XPEV Xpeng Inc
PTON Peloton Interactive Inc
PEB Pebblebrook Hotel Trust
VFC VF Corp
BWG BrandywineGLOBAL ? Global Income Opportunities Fund
BPYPO Brookfield Property Partners LP
HLAHU Hamilton Lane Alliance Holdings I Inc
Go

Consumer Staples : Household Products | Mid Cap Blend
Company profile

The Clorox Company is a multinational manufacturer and marketer of consumer and professional products. The Company operates through four segments: Health and Wellness, Household, Lifestyle and International. The Health and Wellness segments consist of cleaning products, professional products and vitamins, minerals and supplements mainly marketed and sold in the United States. The Household segment consists of bags and wraps, grilling products and cat litter marketed and sold in the United States. The Lifestyle segment consists of food, natural personal care products and water-filtration products marketed and sold in the United States. The International segment consists of products sold outside the United States. The Company's products are sold primarily through mass retailers; grocery outlets; warehouse clubs; dollar stores; home hardware centers; drug, pet and military stores; third-party and owned e-commerce channels, and distributors.

Closing Price
$149.86
Day's Change
1.21 (0.81%)
Bid
--
Ask
--
B/A Size
--
Day's High
151.19
Day's Low
148.48
Volume
(Below Average)
Volume:
1,254,573

10-day average volume:
1,423,958
1,254,573

Numinus Expands Ketamine Therapy for Mental Health in Montreal and announces new brand awareness initiatives

7:00 am ET September 22, 2022 (PR Newswire) Print

-- New Montreal space will focus on treating depression, addiction and other common disorders

-- Numinus announces sponsorship of East Forest North American tour

-- Company also announces new PR and Marketing partners

Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced the opening of a new clinic in Montreal that will replace an existing downtown clinic. The new site, in the Plateau neighbourhood, will have expanded capacity to offer ketamine treatments, including a wider assortment of ketamine-assisted therapy options.

"There is significant research showing ketamine can be highly effective in treating depression, addiction, trauma and anxiety, and other common mental health disorders," said Jason Lapensee, Numinus SVP, Clinical Operations. "Numinus is taking this evidence into consideration as we continue to expand our clinic network and treatment programs across North America."

Numinus continues to focus on the safe, evidence-based use of ketamine in combination with traditional therapy. Expanded services will include different administrations of ketamine, including Spravato, intramuscular, lozenge and nasal spray, along with options in treatment length and session type. Numinus currently offers a six-week ketamine-assisted therapy program for indications including depression, addiction, and trauma and anxiety. New services will include the option to access ketamine as a standalone treatment, allowing clients to complement prior ketamine-assisted therapy, use it as an emergency antidepressant, or use it in conjunction with therapy from an external health provider. This service flexibility will provide greater access to clients by accommodating differing needs and financial means. Additionally, Numinus will continue to support access for clients in need through the federal Special Access Program, with dedicated space appropriately designed for psilocybin- and MDMA-assisted therapies.

"Numinus recognizes that people in Montreal can benefit from having more treatment options, including ketamine," said Payton Nyquvest, Numinus Founder and CEO. "Expanding our services here is another important step towards improving access to best-in-class and innovative mental healthcare in Quebec, while continuing to expand our clientele and market presence."

Numinus currently operates 13 clinics across Canada and the US, including locations in British Columbia, Ontario, Arizona and Utah, with comprehensive services ranging from mental health therapy to neurologic care, and additionally supports clients in accessing psychedelic-assisted therapy through Canada's federal Special Access Program.

More information about Numinus' Montreal locations can be found at: www.numinus.com/location/montreal.

Numinus sponsors East Forest Ceremony North American tour

Numinus is pleased to sponsor the North American 'Ceremony' tour by leading musician, East Forest. The tour will combine live music and guided meditation for an immersive concert-ritual experience across 15 cities, including Los Angeles, Salt Lake City, San Francisco, Seattle and Vancouver (BC). The collaboration offers an opportunity to drive cultural awareness around psychedelic-assisted therapy and mental health, while also driving increased brand awareness for Numinus.

Update on PR, Marketing and Awareness service providers

Numinus is pleased to announce that it has recently engaged Autumn Communications for public relations, executive communications, and media strategy, catering to the US market. Autumn Communications is a full-service public relations and marketing firm with offices in New York City and Los Angeles that specializes in developing compelling campaigns that amplify brand awareness, engage customers, and drive demand.

Numinus has also engaged Native Ads, Inc. to provide digital media services, marketing and data analytics services to the Company. Native Ads is a full-service advertising agency, that owns and operates a proprietary ad exchange with over 80 integrated supply side platforms. Neither Native Ads nor any of its directors and officers own any securities of the Company.

About Numinus

Numinus Wellness (TSX: NUMI) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model - including psychedelic production, research and clinic care - is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.

Learn more at numinus.com and follow us on LinkedIn, Facebook, Twitter, and Instagram.

Disclaimer

Neither Numinus Wellness Inc., nor any of its subsidiaries is a professional corporation licensed to practice health services. In jurisdictions where health services may only be provided by a corporation if that corporation holds a valid permit to do so, Numinus and its subsidiaries operate in a management services function to affiliated professional corporations, who provide health services to patients. Numinus and its subsidiaries do provide health services directly to patients in those jurisdictions where authorized to do so.

Forward-looking statements

This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs regarding future performance are "forward-looking statements". Forward-looking statements can be identified by the use of words such as "expects", "does not expect", "is expected", "believes", "intends", "anticipates", "does not anticipate", "believes" or variations of these words, expressions or statements, that certain actions, events or results "may", "could", "would", "might" or "will be" taken, will occur or will be realized. Such forward-looking statements involve risks, uncertainties and other known and unknown factors that could cause actual results, events or developments to differ materially from the results, events or developments expected and expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, dependence on obtaining and maintaining regulatory approvals, including the acquisition and renewal of federal, provincial, municipal, local or other licenses, and any inability to obtain all necessary government authorizations, licenses and permits to operate and expand the Company's facilities; regulatory or policy changes such as changes in applicable laws and regulations, including federal and provincial legalization, due to fluctuations in public opinion, industry perception of integrative mental health, including the use of psychedelic-assisted therapy, delays or inefficiencies or any other reason; any other factor or development likely to hamper the growth of the market; the Company's limited operating and profitability track record; dependence on management; the Company's need for additional financing and the effects of financial market conditions and other factors on the availability of capital; competition, including that of more established and better funded competitors; the impact of the Russia-Ukraine conflict on the global economy; the continued impact of the COVID-19 pandemic; and the need to build and maintain alliances and partnerships, including with research and development companies, customers and suppliers. These factors should be carefully considered, and readers are cautioned not to place undue reliance on forward-looking statements. Despite the Company's efforts to identify the main risk factors that could cause actual measures, events or results to differ materially from those described in forward-looking statements, other risk factors may cause measures, events or developments to materially differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company does not undertake to revise forward-looking statements, even if new information becomes available as a result of future events, new facts or any other reason, except as required by applicable laws.

https://c212.net/c/img/favicon.png?sn=TO81059&sd=2022-09-22

View original content:https://www.prnewswire.com/news-releases/numinus-expands-ketamine-therapy-for-mental-health-in-montreal-and-announces-new-brand-awareness-initiatives-301630756.html

SOURCE Numinus Wellness Inc.

https://rt.prnewswire.com/rt.gif?NewsItemId=TO81059&Transmission_Id=202209220700PR_NEWS_USPR_____TO81059&DateId=20220922

comtex tracking

COMTEX_415029340/1005/2022-09-22T07:00:15

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.